Clinical Trials Logo

Clinical Trial Summary

TQB2928 is a promising new molecular entity that mediates blockade of CD47 and SIRPĪ± and enhances the phagocytosis of cancer cells by macrophages. In preclinical in vivo models, TQB2928 was active against a wide range of solid tumors and hematologic malignancies. This is the first-in-human phase 1 trial of TQB2928 in patients with advanced solid tumors and hematological malignancies.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04854681
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status Not yet recruiting
Phase Phase 1
Start date August 1, 2021
Completion date December 1, 2022